Discovering The Potential Uses of IGHV1-2 (G28474)

Target Name: IGHV1-2

NCBI ID: G28474

IGHV1-2

Other Name(s): IGHV12 | immunoglobulin heavy variable 1-2 | V35 | Immunoglobulin heavy variable 1-2

Discovering The Potential Uses of IGHV1-2

IGHV1-2 (Immunoglobulin Heavy Chain V1/V2) is a type of protein that is expressed in the human body and is found in various tissues, including the liver, spleen, and bone marrow. It is a component of the immune system and plays a crucial role in the body's fight against infection and disease.

One of the unique features of IGHV1-2 is its structure. It consists of four polypeptide chains that are held together by disulfide bonds. These chains are composed of different amino acids, which are the building blocks of proteins. The two chains in the middle of the molecule contains four constant amino acids that are the same for all individuals, while the other two chains contain variable amino acids that are different from person to person.

The IGHV1-2 molecule has several potential uses as a drug target or biomarker. One of the most promising aspects of IGHV1-2 is its ability to be targeted by small molecules, which makes it a potential candidate for use in drug development. The molecule's variable amino acids make it possible to tailor the molecule to specifically interact with certain molecules, which could allow for more effective and targeted treatments.

Another potential use of IGHV1-2 is as a biomarker for certain diseases. The molecule is often present in the blood, and its levels can be affected by a variety of factors, including infection and inflammation. By measuring the levels of IGHV1-2 in the blood, researchers can gain insights into the health of the individual and potentially identify the early signs of certain diseases. This could make IGHV1-2 an effective diagnostic tool for diseases such as cancer, HIV, and hepatitis.

IGHV1-2 is also a potential biomarker for autoimmune diseases. Many autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, involve an overactive immune system that attacks the body's own tissues. IGHV1-2 is present in the blood and has been suggested as a potential biomarker for these diseases. By measuring the levels of IGHV1-2 in the blood, researchers can gain insights into the immune system's activity and potentially identify new targets for treatment.

In addition to its potential uses as a drug target or biomarker, IGHV1-2 is also of interest to researchers because of its unique structure. The molecule's four polypeptide chains and disulfide bonds make it a complex biomolecule that is difficult to study. By using techniques such as mass spectrometry, researchers have been able to study the IGHV1-2 molecule in great detail and gain insights into its molecular structure and function.

Overall, IGHV1-2 is a fascinating molecule that has a wide range of potential uses as a drug target or biomarker. Its unique structure and ability to be targeted by small molecules make it an attractive candidate for drug development, while its presence in the immune system and potential as a biomarker for autoimmune diseases makes it an important molecule to study further. Further research is needed to fully understand the IGHV1-2 molecule and its potential uses in the fight against disease.

Protein Name: Immunoglobulin Heavy Variable 1-2

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV1-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV1-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets